SEARCH

SEARCH BY CITATION

References

  • 1
    Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional relationships of the interleukins. J Exp Med 151: 15511556, 1980
  • 2
    Dinarello CA: Interleukin-1. Rev Infect Dis 6: 5195, 1984
  • 3
    Muegge K, Oppenheim JJ: IL-1 in autoimmunity. In, Molecular Autoimmunity. Edited by NTalal. London, Academic Press, 1991
  • 4
    Hopkins SJ, Humphreys M, Jayson MIV: Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 72: 422427, 1988
  • 5
    Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 31: 480486, 1988
  • 6
    Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet ii: 706709, 1988
  • 7
    North J, Situnayake RD, Tikly M, Cremona A, Nicoll J, Kumararatne DS, Nuki G: Interleukin 1 beta, hand and foot bone mineral content and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 53: 543546, 1994
  • 8
    Miller VE, Rogers K, Muirden KD: Detection of tumour necrosis factor alpha and interleukin-1 beta in the rheumatoid osteo-arthritic cartilage-pannus junction by immunohistochemical methods. Rheumatol Int 13: 7782, 1993
  • 9
    Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 54: 167227, 1993
  • 10
    Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC: Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 341: 146148, 1993
  • 11
    Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37: 644652, 1994
  • 12
    Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336340, 1990
  • 13
    Eisenberg SP, Evans RJ, Arend WP, Verderber E: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 341346, 1990
  • 14
    Henderson B, Thompson RC, Hardingham T, Lewthwaite J: Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 3: 246249, 1991
  • 15
    Van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237243, 1994
  • 16
    Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 13051314, 1993
  • 17
    Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC: Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 59: 44364442, 1991
  • 18
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315324, 1988
  • 19
    Ware JE Jr: SF-36 Health Survey Manual and Interpretation Guide. Boston, MA, Health Institute, New England Medical Center, 1993
  • 20
    Silman AJ: Rheumatoid arthritis. In, Epidemiology of the Rheumatic Diseases. Edited by AJSilman, MCHochberg. Oxford, Oxford University Press, 1993
  • 21
    Fries JF, Williams CA, Ramey D, Bloch DA: The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36: 297306, 1993
  • 22
    Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, Campion M, Chizzonite R: Incidence and clinical significance of neutralizing antibodies in patients receiving interferon-alpha 2a. J Interferon Res 9 (Suppl 1): S9S15, 1989
  • 23
    Maier SF, Wiertelak EP, Martin D, Watkins LR: Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623: 321324, 1993
  • 24
    Ballou P, Kushner I: Laboratory evaluation of inflammation. In, Textbook of Rheumatology. Fourth edition. Edited by WNKelley, EDHarrisJr, SRuddy, CBSledge. Philadelphia, WB Saunders, 1993
  • 25
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 16811690, 1993
  • 26
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 11051110, 1994